<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418873</url>
  </required_header>
  <id_info>
    <org_study_id>LPRIS-0601-TW</org_study_id>
    <nct_id>NCT00418873</nct_id>
  </id_info>
  <brief_title>Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward</brief_title>
  <official_title>A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and tolerability of zotepine versus
      Risperidone in aggressive schizophrenic patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped due to difficulty in patient enrollment
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in aggression behavior assessed using the Positive and Negative Syndrome Scale Excited Component (PANSS-EC) score.</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the total score of Positive and Negative Syndrome Scale</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Clinical Global Impression (CGI)</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1. Zotepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zotepine</intervention_name>
    <description>Oral</description>
    <arm_group_label>1. Zotepine</arm_group_label>
    <other_name>Lodopin速</other_name>
    <other_name>Zoleptil速</other_name>
    <other_name>Nipolept速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Oral</description>
    <arm_group_label>2. Risperidone</arm_group_label>
    <other_name>Risperdal速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 65 years, male or female

          -  In-patients suffering from schizophrenia according to DSM-IV diagnostic criteria with
             PANSS total score of greater than or equal to 60.

          -  Patients with PANSS-EC total score of greater than or equal to 14 and with at least
             one PANSS-EC symptom score greater than or equal to 4

        Exclusion Criteria:

          -  Patients with history of seizure or with alcohol or substance abuse in the last 6
             months

          -  Diabetes, Parkinson's disease or phaeochromocytoma

          -  Patients with hypertension and current use of antihypertensive agents

          -  Women who are pregnant, lactating or intend to become pregnant during the study period

          -  Poor response to two different antipsychotics in full dose and full course or use of
             clozapine previously

          -  Renal, hepatic, haematologic disease or other conditions may not suitable for the
             study based on investigator's evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Jer Tsai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei City Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bali</city>
        <state>Taipei county</state>
        <zip>249</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>330</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma Inc.</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>zotepine</keyword>
  <keyword>risperidone</keyword>
  <keyword>second generation antipsychotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Zotepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

